Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

AMAG Pharmaceutocals Reveal Positive Results From Phase III Study Of Feraheme

RELATED NEWS
Trade AMAG now with 

AMAG Pharmaceuticals Inc (AMAG: Quote) Wednesday announced positive preliminary results from the second phase III study for Feraheme in patients with iron deficiency anemia or IDA, regardless of the underlying cause.

The biopharmaceutical company stated that the study, called as IDA-301, compared Feraheme treatment to placebo and enrolled patients having IDA associated with various conditions including abnormal uterine bleeding, cancer, gastrointestinal disorders or other causes.

The company further stated that Feraheme demonstrated superiority on all primary efficacy endpoints evaluated in this study.

The company added that the efficacy and safety of Feraheme in this study were comparable to that reported in the IDA-302 study, the phase III IDA study comparing Feraheme to iron sucrose.

In the IDA-301 study, Feraheme demonstrated robust efficacy, achieving superiority on both primary efficacy endpoints. Patients treated with Feraheme achieved a statistically significant mean increase in hemoglobin at week five of 2.7 g/dL, compared to a mean increase of only 0.1 g/dL in patients who received placebo; importantly, these data are consistent with the 2.7 g/dL increase in hemoglobin reported in the IDA-302 study,

Register
To receive FREE breaking news email alerts for AMAG Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
South Korea announced a $11.4 billion stimulus plan to stimulate the economy, which logged its slowest growth in more than a year on weak private spending. The finance ministry announced policy financing support for small businesses and to boost household income. The ministry increased the lending ceiling for businesses to $15 billion from $10 billion. European stocks are seen flat to slightly lower on Thursday amid a lack of cues to sustain two days of gains. Geopolitical concerns remain and the earnings season is picking up pace, rendering investor mood cautious. In economic releases, investors eye PMI reports from major European economies and... Social networking giant Facebook, Inc. said Wednesday after the markets closed that its second quarter profit more than doubled from last year, as revenue surged 61% amid strong growth in mobile advertising. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.